Beryl Drugs Limited (524606) fair value: what the stock is really worth
As of Oct 1, 2026: fair value of Beryl Drugs Limited ₹14.29, price ₹25.29, upside -43.5%, quality 51 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Beryl Drugs Limited for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
60‑month range ₹5.43 – ₹44.40 · fair‑value band ₹11.95 – ₹18.58 · the ₹25.29 price screens above the ₹14.29 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.
Follow Beryl Drugs in your weekly email
Every Wednesday you see whether Beryl Drugs is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Beryl Drugs Limited manufactures and markets branded and generic pharmaceutical formulations in India. The company offers I.V. fluids and small volume injectables, as well as veterinary products. It also provides research and development, and contract manufacturing services. Beryl Drugs Limited was founded in 1993 and is based in Indore, India.
Stock analysis
Beryl Drugs Limited (524606) currently trades at ₹25.29, while our model-based Fair Value estimate is ₹14.29, 43.5% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Multiples group reads highest at a median of ₹18.43 per share, and 2 of the 12 models we run sit above the ₹25.29 price.
Bear case: the Earnings-Based group reads lowest at ₹11.45, and 10 of the 12 models stay below the price. Evidence for this calculation is low.
Scenario range: ₹11.95 (bear) to ₹18.58 (bull), the price of ₹25.29 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 51/100 (solid quality), in the Healthcare sector.
Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Beryl Drugs Limited reported revenue of ₹188M in FY2026 versus ₹145M in FY2022, a compound +6.8%/yr. Reported net income was ₹4.2M in FY2026.
Key figures
Market cap ₹30.6M (≈ $318K) · P/E ratio 4.6 · P/S ratio 0.10 · EPS (TTM) ₹1.30 · Net margin 2.3% · Return on assets (EBIT) 3.0% · Operating margin −0.4% · Revenue (TTM) ₹113M.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 50 out of 100 (low confidence).
What moves the price
The share trades about 1% below its 52-week high and 50% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −10% fair-value upside, at −44%, 524606 screens richer than that median.
Fair Value models
Bear ₹11.95Fair Value ₹14.29Bull ₹18.58
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2026 figures (about 6 months old). Earnings retained since then (₹0.6625 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.20/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
−11.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−11.2%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+6.3%
Start year 2021 (pandemic). Over 10 years: +3.7% a year
Revenue growth 12 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+2.1%
’14
’15
’16
’17
’18
’19
’21
’22
’23
’24
’25
’26
What shareholders gained per year (last 5 years), in INR ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Basis: EBIT basis. Measured in INR: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+37.1%
Earnings growth per share plus dividend.
Earnings per share, growth per year+37.1%
Dividend (yield on the price)0.0%
Profit margin 2021 to 2026 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.1% → 5%
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its sector: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median. (Industry “Drugs - Generic” was too small, so the broader sector is used.)Health Care · 2462 stocks
Beats the sector median on 1/8 measures
Overall it trails its sector peers.
Valuation
Quality Score51 · Below median
Fair Value upside−44.2% · Below median
Profitability
Return on assets0.0% · Below median
Net margin (TTM)−4.4% · Below median
Operating margin (TTM)−0.4% · Below median
Growth and dividend
Revenue growth−36.3% · Bottom 25%
Dividend yield (TTM)0.0% · Bottom 25%
Valuation Multiplesvs Health Care median · lower = cheaper
P/E (TTM)4.6× · Cheapest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 7
FUTURE (revenue growth)0· sector 25
PAST (return on equity)0· sector 13
HEALTH (low debt)100· sector 96
DIVIDEND (yield)0· sector 33
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Beryl Drugs Limited (524606) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of ₹14.29 versus a price of ₹25.29, about −44% upside (overvalued).
What is the fair value of 524606?
Our model-based fair value for Beryl Drugs Limited is ₹14.29 (as of Sep 24, 2026), built from audited fundamentals. The current price: ₹25.29.
What is the quality score of 524606?
Beryl Drugs Limited has a Quality Score of 51/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Beryl Drugs Limited (524606)?
Our model-based price target is the fair value of ₹14.29 (as of Sep 24, 2026) from 12 valuation models. Cautious scenario ₹11.95, optimistic scenario ₹18.58. It is a calculation from audited fundamentals, not an analyst target.
What is the Beryl Drugs Limited stock forecast for 2026?
Our models put fair value at ₹14.29, about −44% upside versus a price of ₹25.29 (overvalued). Cautious scenario ₹11.95, optimistic scenario ₹18.58. The calculation is refreshed regularly with new filings.
What is the revenue of Beryl Drugs Limited (524606)?
Beryl Drugs Limited reported trailing-twelve-month revenue of about ₹113M (latest available figure, as of Sep 24, 2026).
What is the intrinsic value of Beryl Drugs Limited (524606)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Beryl Drugs Limited it is ₹14.29 per share (as of Sep 24, 2026), against a price of ₹25.29. It is the blended result of 12 valuation models (cash flow, earnings, asset, dividend).
Is Beryl Drugs Limited stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 524606 trades above its calculated fair value: price ₹25.29, fair value ₹14.29, a gap of about −44% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 524606?
No. The price is what the market pays today (₹25.29); the fair value is what the company's own numbers justify (₹14.29). For Beryl Drugs Limited the two are ₹11.00 per share apart. That gap is exactly why we show both numbers side by side.
How much is Beryl Drugs Limited worth?
The market values Beryl Drugs Limited at about ₹30.6M (market capitalisation, as of Sep 24, 2026). Per share that is ₹25.29; our models calculate a fair value of ₹14.29 per share.
What do the bullish and bearish scenarios say about 524606?
Our models span a range for Beryl Drugs Limited: cautious scenario ₹11.95, base ₹14.29, optimistic ₹18.58 per share (as of Sep 24, 2026, price ₹25.29). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 524606?
Beryl Drugs Limited trades at a price-to-earnings ratio of 4.6 (as of Sep 24, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ₹14.29 is built from several models across several years.
How far is 524606 from its 52-week high?
Beryl Drugs Limited trades at ₹25.29, about 1% below its 52-week high of ₹25.65 and 50% above the low of ₹16.87 (as of Oct 1, 2026). Distance from the high says nothing about value: that is what the fair value of ₹14.29 is for.
Which stocks are comparable to Beryl Drugs Limited?
From the same area (Healthcare) we also value Anuh Pharma Limited, Eli Lilly and Company, Johnson & Johnson,, AbbVie Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Beryl Drugs Limited stock attractive at the current price?
The data as of Sep 24, 2026: price ₹25.29, calculated fair value ₹14.29 (−44%), Quality Score 51/100, from 12 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 524606 calculated?
We run Beryl Drugs Limited through 12 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ₹14.29, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Beryl Drugs Limited itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Beryl Drugs Limited (524606)?
The closing price on Oct 1, 2026 was ₹25.29. Our model-based fair value is ₹14.29, about −44% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Beryl Drugs Limited right now?
The price sits above even our optimistic bull case (₹18.58). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (51/100) and above fair value, neither a clear bargain nor a standout compounder.
Key figures of Beryl Drugs Limited
How large is the market capitalisation of Beryl Drugs Limited (524606)?
The market capitalisation of Beryl Drugs Limited is ₹30.6M (≈ $318K). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Beryl Drugs Limited (524606)?
The price-to-sales ratio of Beryl Drugs Limited is 0.10 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Beryl Drugs Limited (524606)?
Earnings per share at Beryl Drugs Limited are ₹1.30 (price ÷ EPS = P/E 4.6). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Beryl Drugs Limited (524606)?
The net margin of Beryl Drugs Limited is 2.3% (fiscal year 2026). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the EBIT return on assets of Beryl Drugs Limited (524606)?
On an EBIT basis the return on assets of Beryl Drugs Limited is 3.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Beryl Drugs Limited (524606)?
The operating margin of Beryl Drugs Limited is −0.4% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Beryl Drugs Limited (524606)?
Revenue at Beryl Drugs Limited is growing −36.3% versus a year earlier (3y avg −11.2%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Beryl Drugs Limited (524606) generate?
The free cash flow of Beryl Drugs Limited is −₹1.7M (fiscal year 2026). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Beryl Drugs Limited (524606) carry?
The net debt of Beryl Drugs Limited is ₹21.2M (fiscal year 2026). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Beryl Drugs Limited in the live analysis
One click puts Beryl Drugs Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
